Home/Clearside Biomedical/Charles A. Deignan

CA

Charles A. Deignan

Chief Financial Officer

Clearside Biomedical

Therapeutic Areas

Ophthalmology Retinal Diseases

Clearside Biomedical Pipeline

Drug	Indication	Phase
CLS-AX (axitinib injectable suspension)	Wet Age-Related Macular Degeneration (AMD)	Phase 3 Ready
XIPERE® (triamcinolone acetonide)	Macular Edema Associated with Uveitis	Approved
CLS-AX	Diabetic Macular Edema (DME)	Preclinical

Leadership Team at Clearside Biomedical

George Lasezkay

President and Chief Executive Officer

Thomas A. Ciulla

Chief Medical Officer

Benjamin R. Yerxa

Chief Technology Officer and Co-Founder

View full Clearside Biomedical profile